Year archive

GeoVax Labs, Inc. — 2026 filings

All 60 regulatory filings released by GeoVax Labs, Inc. (GOVX) in 2026, sourced directly from the official regulator.

60 Filings

2026 Period

2026 filings (60)

Filing	Released	Lang
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms Regulatory Filings	2026-05-20	English
FORM 8-K Regulatory Filings	2026-05-19	English
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules Capital/Financing Update	2026-05-18	English
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans Earnings Release Q1 2026	2026-05-14	English
FORM 8-K Regulatory Filings	2026-05-14	English
FORM 10-Q Interim / Quarterly Report	2026-05-14	English
Major Shareholding Notification 2026 Major Shareholding Notification	2026-05-13	English
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors Regulatory Filings	2026-05-13	English
PRER14A Regulatory Filings	2026-05-08	English
FORM 8-K Regulatory Filings	2026-05-07	English
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway Regulatory Filings	2026-05-06	English
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities Regulatory Filings	2026-04-29	English
FORM DEF 14A Proxy Solicitation & Information Statement	2026-04-27	English
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies Regulatory Filings	2026-04-27	English
Regulatory Filings 2026 Regulatory Filings	2026-04-22	English
Regulatory Filings 2026 Regulatory Filings	2026-04-22	English
Regulatory Filings 2026 Regulatory Filings	2026-04-20	English
Regulatory Filings 2026 Regulatory Filings	2026-04-20	English
Regulatory Filings 2026 Regulatory Filings	2026-04-20	English
Regulatory Filings 2026 Regulatory Filings	2026-04-20	English
Regulatory Filings 2026 Regulatory Filings	2026-04-20	English
FORM POS EX Regulatory Filings	2026-04-17	English
FORM POS EX Regulatory Filings	2026-04-17	English
FORM POS EX Regulatory Filings	2026-04-17	English
FORM POS EX Regulatory Filings	2026-04-17	English
FORM POS EX Regulatory Filings	2026-04-17	English
FORM PRE 14A Regulatory Filings	2026-04-16	English
POS AM Regulatory Filings	2026-04-16	English
POS AM Regulatory Filings	2026-04-16	English
POS AM Regulatory Filings	2026-04-16	English
POS AM Regulatory Filings	2026-04-16	English
POS AM Regulatory Filings	2026-04-16	English
FORM S-1 Regulatory Filings	2026-04-15	English
FORM S-1 Regulatory Filings	2026-04-15	English
8-K - GeoVax Labs, Inc. (0000832489) (Filer) Regulatory Filings	2026-04-15	English
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update Earnings Release FY 2025	2026-04-15	English
10-K - GeoVax Labs, Inc. (0000832489) (Filer) Annual Report FY 2025	2026-04-15	English
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market Regulatory Filings	2026-04-14	English
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026 Regulatory Filings	2026-04-02	English
FORM 8-K Regulatory Filings	2026-03-31	English
FORM NT 10-K Regulatory Filings	2026-03-31	English
GeoVax Announces a Warrant Inducement Transaction Capital/Financing Update	2026-03-31	English
GeoVax Provides Update on GEO-MVA Program Regulatory Filings	2026-03-25	English
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients Regulatory Filings	2026-03-12	English
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine Regulatory Filings	2026-03-11	English
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors Regulatory Filings	2026-02-24	English
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology Regulatory Filings	2026-02-18	English
Major Shareholding Notification 2026 Major Shareholding Notification	2026-02-18	English
8-K - GEOVAX LABS, INC. (0000832489) (Filer) Regulatory Filings	2026-02-17	English
FORM 424B5 Regulatory Filings	2026-02-17	English
GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over Regulatory Filings	2026-02-17	English
Major Shareholding Notification 2026 Major Shareholding Notification	2026-02-17	English
Major Shareholding Notification 2026 Major Shareholding Notification	2026-02-13	English
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Capital/Financing Update	2026-02-13	English
SCHEDULE 13G Filing Major Shareholding Notification	2026-02-11	English
424B5 Filing Regulatory Filings	2026-01-26	English
GeoVax Highlights 2026 as a Pivotal Year for Progress Regulatory Filings	2026-01-20	English
8-K Filing Regulatory Filings	2026-01-12	English
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement Share Issue/Capital Change	2026-01-08	English
GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week Regulatory Filings	2026-01-06	English

Filings by year

2026 60 filings
2025 94 filings
2024 98 filings
2023 48 filings
2022 55 filings
2021 47 filings
2020 54 filings
2019 36 filings
2018 32 filings
2017 37 filings
2016 60 filings
2015 57 filings
2014 37 filings
2013 42 filings
2012 43 filings
2011 20 filings
2010 90 filings
2009 48 filings
2008 43 filings
2007 37 filings
2006 31 filings